Cargando…

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment

BACKGROUND: Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortiox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basurte-Villamor, Ignacio, Vega, Pablo, Roncero, Carlos, Martínez-Raga, José, Grau-López, Lara, Aguilar, Lourdes, Torrens, Marta, Szerman, Nestor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081619/ https://www.ncbi.nlm.nih.gov/pubmed/35547266 http://dx.doi.org/10.2147/NDT.S358782

Ejemplares similares

Professionals’ perceptions about healthcare resources for co-occuring disorders in Spain
por: Roncero, Carlos, et al.
Publicado: (2014)

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
por: Szerman, Nestor, et al.
Publicado: (2020)

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
por: Szerman, Nestor, et al.
Publicado: (2020)

Results of a Hepatitis C Micro-Elimination Program in Two Addiction Centers Among Subjects With Substance Use Disorder
por: Vega-Astudillo, Pablo, et al.
Publicado: (2022)

Gambling Dual Disorder: A Dual Disorder and Clinical Neuroscience Perspective
por: Szerman, Nestor, et al.
Publicado: (2020)

Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
por: Kotzalidis, Georgios D., et al.
Publicado: (2021)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Latent Impulsivity Subtypes in Substance Use Disorders and Interactions with Internalizing and Externalizing Co-Occurring Disorders
por: Marín-Navarrete, Rodrigo, et al.
Publicado: (2018)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment
por: Gimeno, Carmen, et al.
Publicado: (2017)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Major depression with musical obsession treated with vortioxetine: a case report
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
por: Kelliny, Marc, et al.
Publicado: (2015)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
por: Bennabi, Djamila, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
por: Xiong, Shihong, et al.
Publicado: (2022)

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
por: Di Nicola, Marco, et al.
Publicado: (2023)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis
por: Meeker, Amanda S, et al.
Publicado: (2015)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study
por: Kim, Hong, et al.
Publicado: (2021)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
por: Mattingly, Gregory W., et al.
Publicado: (2022)

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
por: Li, Zejun, et al.
Publicado: (2023)

Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
por: Manna, Chayan K., et al.
Publicado: (2023)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_elv7fuvs28fgib8ktcua7d7up1